Develops and commercializes therapies for rare and ultra-rare genetic diseases. Now — the numbers.
The biggest line carries real weight, but it doesn’t decide everything on its own.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 18% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 2.1× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 22% of them.
Analysts' average target sits 94% above today's price.
An investor who bought at the very peak is down 84% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 18% a year on average.
The company sells $673M a year; the problem isn’t sales — it’s costs running above that number.
A loss of $575M against $673M in annual sales.
At the current pace of spending, the cash lasts about 1.2 years. After that, the company needs to find new money.
On our five-subject report card, RARE sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: RARE has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (22/100) says the stock isn’t cheap.